Intellia Therapeutics Inc (NASDAQ: NTLA) on Tuesday, plunged -1.37% from the previous trading day, before settling in for the closing price of $21.83. Within the past 52 weeks, NTLA’s price has moved between $20.78 and $47.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 12.09% over the last five years. The company achieved an average annual earnings per share of -2.45%. With a float of $94.22 million, this company’s outstanding shares have now reached $96.44 million.
The firm has a total of 526 workers. Let’s measure their productivity.
Intellia Therapeutics Inc (NTLA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Intellia Therapeutics Inc is 2.30%, while institutional ownership is 88.42%. The most recent insider transaction that took place on Mar 04 ’24, was worth 75,778. In this transaction EVP, General Counsel of this company sold 2,297 shares at a rate of $32.99, taking the stock ownership to the 81,571 shares. Before that another transaction happened on Mar 04 ’24, when Company’s EVP, Chief Technical Officer sold 605 for $32.99, making the entire transaction worth $19,959. This insider now owns 71,470 shares in total.
Intellia Therapeutics Inc (NTLA) Earnings and Forecasts
As on 12/31/2023, Multinational firm has announced its last quarter scores, in which it reported -1.17 earnings per share (EPS) for the period topping the consensus outlook (set at -1.4) by 0.23. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -2.45% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.00% during the next five years compared to -22.30% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Intellia Therapeutics Inc (NTLA) is currently performing well based on its current performance indicators. A quick ratio of 8.67 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 57.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.42, a number that is poised to hit -1.38 in the next quarter and is forecasted to reach -5.64 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Analysing the last 5-days average volume posted by the [Intellia Therapeutics Inc, NTLA], we can find that recorded value of 1.11 million was lower than the volume posted last year of 1.5 million. As of the previous 9 days, the stock’s Stochastic %D was 17.45%. Additionally, its Average True Range was 1.24.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 5.32%, which indicates a significant decrease from 13.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.11% in the past 14 days, which was lower than the 58.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.97, while its 200-day Moving Average is $30.97. Now, the first resistance to watch is $22.42. This is followed by the second major resistance level at $23.31. The third major resistance level sits at $23.77. If the price goes on to break the first support level at $21.07, it is likely to go to the next support level at $20.61. Should the price break the second support level, the third support level stands at $19.72.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
Market capitalization of the company is 2.08 billion based on 96,439K outstanding shares. Right now, sales total 36,280 K and income totals -481,190 K. The company made 11,990 K in profit during its latest quarter, and -122,220 K in sales during its previous quarter.
